Evidence map›Paper›PMID 39920771›Full record

ReviewJournal of translational medicine2025

Targeting ferroptosis in prostate cancer management: molecular mechanisms, multidisciplinary strategies and translational perspectives.

Hubo Yang, Xuefeng Zhang, Zongming Jia, He Wang, Jixiang Wu, Xuedong Wei, Yuhua Huang, Wenying Yan, Yuxin Lin

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. International journal of molecular sciences · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hubo Yang *Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Xuefeng Zhang *Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Zongming Jia *Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
He WangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Jixiang WuDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Xuedong WeiDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Yuhua HuangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. sdfyyhyh@163.com.
Wenying YanSuzhou Key Lab of Multi-modal Data Fusion and Intelligent Healthcare, Suzhou, 215104, China. wyyan@suda.edu.cn.ORCID 0000-0001-5016-575X
Yuxin LinDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. linyuxin@suda.edu.cn.ORCID 0000-0001-6543-0317

Funding

National Natural Science Foundation of China 32200533Natural Science Foundation of Jiangsu Province BK20241796
6 · The paper itself

Abstract

Prostate cancer (PCa) is a kind of malignant solid tumor commonly observed among males worldwide. The dilemma of increasing incidence with therapeutic resistance has become the leading issue in PCa clinical management. Ferroptosis is a new form of regulatory cell death caused by iron-dependent lipid peroxidation, which has a dual role in PCa evolution and treatment due to the multi-omics cascade of interactions among pathways and environmental stimuli. Hence deciphering the role of ferroptosis in carcinogenesis would provide novel insights and strategies for precision medicine and personalized healthcare against PCa. In this study, the mechanisms of ferroptosis during cancer development were summarized both at the molecular and tumor microenvironment level. Then literature-reported ferroptosis-related signatures in PCa, e.g., genes, non-coding RNAs, metabolites, natural products and drug components, were manually collected and functionally compared as drivers/inducers, suppressors/inhibitors, and biomarkers according to their regulatory patterns in PCa ferroptosis and pathogenesis. The state-of-the-art techniques for ferroptosis-related data integration, knowledge identification, and translational application to PCa theranostics were discussed from a combinative perspective of artificial intelligence-powered modelling and advanced material-oriented therapeutic scheme design. The prospects and challenges in ferroptosis-based PCa researches were finally highlighted to light up future wisdoms for the flourishing of current findings from bench to bedside.

Indexed as

FerroptosisMolecular Targeted TherapyProstatic NeoplasmsTranslational Research, BiomedicalAnimalsHumansMaleTumor MicroenvironmentFerroptosisMultidisciplinary characterizationMulti-omics signaturesProstate cancerTranslational systems biology

Identifiers

PMID39920771
PMCPMC11806579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.